Clinical Trials Network

PET is a very complex imaging modality with many potential sources of human, technical and biological variation/error that can reduce the accuracy and precision of the results of an individual scan. The greater this variation is across all the scans contributing to a given study, the lower the statistical power of the study becomes and the harder it is to detect an effect. Carefully controlling protocols so that these variations/errors are kept to a minimum is therefore essential if PET is to be used most effectively.

Clinical trials involving PET face specific technical and logistical issues associated with standardisation of protocols and the rapid turn-around times necessary for clinical decision making. This is particularly true for multicentre trials where standardisation of all aspects of the procedure is necessary if meaningful and publishable data is to be obtained.

The establishment of networks of accredited scanning sites operating to rigorous standards is now recognised as the way to achieve this.

The NCRI PET Clinical Trials Network

The NCRI PET Clinical Trials Network is intended to provide researchers access to the expertise and resources to conduct cancer clinical trials involving PET along with a co-ordination function for UK-based PET trials. It is based on the PET clinical trials network established by the St Thomas' group in London which has successfully co-ordinated five completed and ongoing UK and international multicentre studies involving more than 20 PET sites.

Currently the UK PET Core Lab can provide the following:

Primary roles:

Secondary roles:

There is no funding available for the core lab functions. Therefore additional funding i.e. over and above the scan costs will continue to be required, in particular for the co-ordination function. Funding for the Core Lab function should be applied for during the grant application process on a per trial basis. Please complete the Request for QA form and send to us at an early stage to obtain costs for your trial.